Evidence map›Paper›PMID 22419935›Full record

ArticleArchives of medical science : AMS2010

The use of whey protein concentrate in management of chronic hepatitis C virus - a pilot study.

Gamal Elattar, Zeinab Saleh, Safinaz El-Shebini, Atif Farrag, Mona Zoheiry, Azza Hassanein, Maged El-Ghannam, Shendy Shendy, Ehab El-Dabaa, Nariman Zahran

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07487623 (Evaluation of the Hepatoprotective Effects of a Nutritional Supplement Containing Resveratrol, Quercetin, Taurine, Inulin, and Whey Protein on Biochemical, Molecular, and Clinical Markers in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07487623 narecruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Hepatoprotective Effects of a Nutritional Supplement Containing Resveratrol, Quercetin, Taurine, Inulin, and Whey Protein on Biochemical, Molecular, and Clinical Markers in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).

TypeinterventionalSponsorUniversity of GuadalajaraRan2025 to 2026Enrolled26ConditionsLiver Disease Chronic, HEPATITIS C VIRUS CHRONIC INFECTIONArmsresveratrol, quercetin, taurine, whey protein, and inulin, whey protein
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Gamal ElattarTheodor Bilharz Research Institute, Imbaba Giza, Egypt.
Zeinab Saleh
Safinaz El-Shebini
Atif Farrag
Mona Zoheiry
Azza Hassanein
Maged El-Ghannam
Shendy Shendy
Ehab El-Dabaa
Nariman Zahran
Theodor Bilharz Research Institute · EGNational Water Research Center · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhey protein contains biologically active ingredients that can prevent and attenuate disease besides being nutritive. The aim of the study was to clarify the effects of oral administration of whey protein on viral load and host defence mechanisms, in particular, phagocytic function of neutrophils, selected immunomodulatory cytokines and serum inflammatory markers, in compensated chronic hepatitis C virus (HCV) patients. MATERIAL AND

methodsTwenty-seven HCV patients (20 males and 7 females) recruited from the hepatology clinic of the Theodor Bilharz Research Institute (TBRI) were given whey protein concentrate (WPC) twice daily for two months. In addition, 15 age and sex matched healthy participants were included in the study, as a control group. Neutrophil phagocytic activity, serum intercellular adhesion molecule (sICAM), interleukin-2 (IL-2), nitric oxide (NO), as well as HCV-RNA levels and routine investigations were determined for patients, before and after WPC supplementation and once for the control group.

resultsThere was a significant decrease in viral load and markers of active inflammation, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), while serum albumin, total leucocyte counts and absolute neutrophil counts showed significant elevation accompanied by improvement of neutrophil phagocytic activity after WPC supplementation compared to pre-treated levels. The oral WPC supplementation was well tolerated without any serious adverse events.

conclusionsOral supplementation of WPC has promising results as a new therapeutic strategy against HCV and its sequelae by decreasing the viral load and active inflammation as well as improving the synthetic capacity of the liver and the phagocytic function of neutrophils, in these patients.

Indexed as

HCVinflammatory markersphagocytic function of neutrophilswhey protein

Identifiers

PMID22419935
PMCPMC3298345
OpenAlexW2122369902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.